The strong clinical data and FDA Priority Review support potential approval and commercialization upside in 2026, but near-term financials reflect heavy pre-launch investment. Traders should monitor topline results from the PIK3CA mutant cohort expected in Q2 2026 and any updates on commercial readiness.
CELC drugs
CELC drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 26 $114.81entry
- T+1 · 8mo ago −7.66%α −5.98% · $106.02
- T+5 · 8mo ago −1.90%α −3.53% · $112.63
- T+20 · 7mo ago +5.42%α −5.25% · $121.03
- T+60 · 5mo ago −21.55%α −35.50% · $90.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celcuity announced strong clinical results from the PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 trial, with gedatolisib showing a median PFS of 16.6 months versus 1.9 months for fulvestrant, alongside FDA acceptance of its NDA with Priority Review and a PDUFA date of July 17, 2026. However, the company reported a widening net loss of $177.0 million in 2025 compared to $111.8 million in 2024, driven by higher R&D and G&A expenses ahead of a potential 2026 launch.
Key Financial Metrics
Key Facts
- FDA accepted NDA for gedatolisib with Priority Review; PDUFA date set for July 17, 2026
- Phase 3 VIKTORIA-1 trial in PIK3CA WT HR+/HER2- ABC showed median PFS of 16.6 months vs 1.9 months (HR=0.14)
- Median time to definitive deterioration in well-being was 23.7 months vs 4.0 months (HR=0.39)
- Full-year 2025 net loss was $177.0 million ($3.79/share), up from $111.8 million ($2.83/share) in 2024
- R&D expenses rose to $145.0 million in 2025 from $104.2 million in 2024, driven by commercial prep and trial activities
- Cash, cash equivalents, and short-term investments totaled $441.5 million at year-end, sufficient to fund operations through 2027
Financial Impact
Increased operating expenses led to a 58% YoY increase in net loss, but cash runway extends to 2027
Risk Factors
- Topline results from the PIK3CA mutant cohort in Q2 2026 may not replicate the wild-type cohort's success
- High operating losses and stock-based compensation could pressure sentiment if cash burn accelerates
- Regulatory risk that FDA may not approve gedatolisib despite Priority Review
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262558 |
Track record
26 reports on CELC
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
- Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
- Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
- Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers